Illumina Past Earnings Performance
Past criteria checks 0/6
Illumina's earnings have been declining at an average annual rate of -62.5%, while the Life Sciences industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 8.1% per year.
Key information
-62.5%
Earnings growth rate
-62.1%
EPS growth rate
| Life Sciences Industry Growth | 12.9% |
| Revenue growth rate | 8.1% |
| Return on equity | -20.2% |
| Net Margin | -25.8% |
| Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Illumina makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,504 | -1,161 | 1,637 | 1,207 |
| 01 Oct 23 | 4,465 | -1,125 | 1,610 | 1,248 |
| 02 Jul 23 | 4,461 | -4,186 | 1,636 | 1,272 |
| 02 Apr 23 | 4,448 | -4,487 | 1,592 | 1,241 |
| 01 Jan 23 | 4,584 | -4,404 | 1,614 | 1,209 |
| 02 Oct 22 | 4,700 | -4,153 | 1,682 | 1,242 |
| 03 Jul 22 | 4,693 | -20 | 1,510 | 1,187 |
| 03 Apr 22 | 4,656 | 701 | 1,550 | 1,061 |
| 02 Jan 22 | 4,526 | 762 | 1,744 | 914 |
| 03 Oct 21 | 4,280 | 907 | 1,351 | 794 |
| 04 Jul 21 | 3,966 | 769 | 1,350 | 696 |
| 04 Apr 21 | 3,473 | 630 | 1,114 | 650 |
| 03 Jan 21 | 3,239 | 656 | 1,014 | 609 |
| 27 Sep 20 | 3,238 | 638 | 813 | 572 |
| 28 Jun 20 | 3,351 | 693 | 811 | 551 |
| 29 Mar 20 | 3,556 | 942 | 835 | 562 |
| 29 Dec 19 | 3,543 | 1,002 | 907 | 575 |
| 29 Sep 19 | 3,458 | 973 | 874 | 607 |
| 30 Jun 19 | 3,405 | 938 | 881 | 615 |
| 31 Mar 19 | 3,397 | 851 | 877 | 600 |
| 30 Dec 18 | 3,333 | 826 | 849 | 568 |
| 30 Sep 18 | 3,243 | 684 | 798 | 538 |
| 01 Jul 18 | 3,103 | 648 | 768 | 513 |
| 01 Apr 18 | 2,936 | 567 | 732 | 492 |
| 31 Dec 17 | 2,752 | 725 | 720 | 500 |
| 01 Oct 17 | 2,594 | 775 | 692 | 488 |
| 02 Jul 17 | 2,487 | 741 | 664 | 480 |
| 02 Apr 17 | 2,424 | 730 | 652 | 474 |
| 01 Jan 17 | 2,398 | 454 | 630 | 458 |
| 02 Oct 16 | 2,371 | 440 | 624 | 450 |
| 03 Jul 16 | 2,314 | 430 | 621 | 423 |
| 03 Apr 16 | 2,253 | 415 | 597 | 395 |
| 03 Jan 16 | 2,220 | 462 | 561 | 362 |
| 27 Sep 15 | 2,141 | 510 | 533 | 348 |
| 28 Jun 15 | 2,071 | 486 | 516 | 334 |
| 29 Mar 15 | 1,979 | 430 | 506 | 321 |
| 28 Dec 14 | 1,861 | 353 | 499 | 306 |
| 28 Sep 14 | 1,736 | 281 | 478 | 294 |
| 29 Jun 14 | 1,612 | 219 | 453 | 279 |
| 30 Mar 14 | 1,511 | 208 | 430 | 264 |
| 29 Dec 13 | 1,421 | 125 | 423 | 249 |
| 29 Sep 13 | 1,343 | 117 | 378 | 212 |
| 30 Jun 13 | 1,272 | 115 | 356 | 195 |
Quality Earnings: ILMN * is currently unprofitable.
Growing Profit Margin: ILMN * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ILMN * is unprofitable, and losses have increased over the past 5 years at a rate of 62.5% per year.
Accelerating Growth: Unable to compare ILMN *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ILMN * is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.5%).
Return on Equity
High ROE: ILMN * has a negative Return on Equity (-20.21%), as it is currently unprofitable.